GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

Rizzo, Manfredi; Nikolić, Dragana; Patti, Angelo Maria; Mannina, Carlo; Montalto, Giuseppe; McAdams, Brooke S.; Rizvi, Ali A.; Cosentino, Francesco

doi:10.1016/j.bbadis.2018.05.012

Cited by 119 publications

(95 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whether the same phenomenon is replicated in human pneumocytes is not known. On the other hand, it should be noted that pioglitazone (31), SGLT2 inhibitors (32), GLP-1RAs (33), and also insulin (34) have shown anti-inflammatory activities, which might be very helpful for patients with COVID-19.…”

Section: Risk Management In People Withmentioning

confidence: 99%

Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era

et al. 2020

View full text Add to dashboard Cite

People with diabetes compared with people without exhibit worse prognosis if affected by coronavirus disease 2019 (COVID-19) induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly when compromising metabolic control and concomitant cardiovascular disorders are present. This Perspective seeks to explore newly occurring cardio-renal-pulmonary organ damage induced or aggravated by the disease process of COVID-19 and its implications for the cardiovascular risk management of people with diabetes, especially taking into account potential interactions with mechanisms of cellular intrusion of SARS-CoV-2. Severe infection with SARS-CoV-2 can precipitate myocardial infarction, myocarditis, heart failure, and arrhythmias as well as an acute respiratory distress syndrome and renal failure. They may evolve along with multiorgan failure directly due to SARS-CoV-2–infected endothelial cells and resulting endotheliitis. This complex pathology may bear challenges for the use of most diabetes medications in terms of emerging contraindications that need close monitoring of all people with diabetes diagnosed with SARS-CoV-2 infection. Whenever possible, continuous glucose monitoring should be implemented to ensure stable metabolic compensation. Patients in the intensive care unit requiring therapy for glycemic control should be handled solely by intravenous insulin using exact dosing with a perfusion device. Although not only ACE inhibitors and angiotensin 2 receptor blockers but also SGLT2 inhibitors, GLP-1 receptor agonists, pioglitazone, and probably insulin seem to increase the number of ACE2 receptors on the cells utilized by SARS-CoV-2 for penetration, no evidence presently exists that shows this might be harmful in terms of acquiring or worsening COVID-19. In conclusion, COVID-19 and related cardio-renal-pulmonary damage can profoundly affect cardiovascular risk management of people with diabetes.

show abstract

Section: Risk Management In People Withmentioning

confidence: 99%

Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It is reported that GLP-1 action is deficient in subjects with type 2 diabetes mellitus [44]. GLP-1 is a protective cytokine against inflammatory events, which in this study is caused by oxidative stress due to the HFFD diet.…”

Section: Discussionmentioning

confidence: 53%

Anthocyanin Extract of Purple Corn Improves Hyperglycemia and Insulin Resistance of Rats Fed High Fat and Fructose Diet via GLP1 and GLP1R Mechanism

Chayati¹,

Sunarti²,

Marsono³

et al. 2019

JFNR

View full text Add to dashboard Cite

Hyperglycemia and insulin resistance are caused by high fat, fructose, or fat and fructose diet. The aim of this study was to investigate the effect of anthocyanin extract of purple corn (AEPC) on insulin resistance of rats fed high fat and fructose diet (HFFD). Insulin resistance was induced by feeding HFFD for 4 weeks and Wistar male rats were orally supplemented with the following treatments for the next six weeks: pioglitazone 1.35 mg kg-1 body weight (bw) as a positive control group (PC), AEPC 6 mg kg-1 bw (LA), AEPC 12.5 mg kg-1 bw (MA), and AEPC 25 mg kg-1 bw (HA), or no treatment as a negative control group (NC). A normal control group was fed a normal diet (NLC) for along 10 weeks. Insulin resistance was indicated by Homeostasis Model Assessments for Insulin Resistance (HOMA-IR) scores. The results showed that HFFD feeding increased HOMA-IR score and blood glucose levels, and decreased levels of plasma glucagon-like peptide 1 (GLP1) and pancreatic glucagon-like peptide 1 receptor (GLP1R). Administration of AEPC reduced HOMA-IR scores and blood glucose levels, increased HOMA-β and HOMA-IS scores, plasma GLP1 and pancreatic GLP1R levels, and improved pancreatic morphology. Our finding suggests that AEPC 12.5 mg kg-1 bw gave the best conditions to improve insulin resistance as well as standard drug administration pioglitazone 1.35 mg kg-1 bw via GLP1 and GLP1R mechanism.

show abstract

“…Dr. Li found that liraglutide attenuated the atherosclerotic lesion and plaque progression in aortic tissues induced by high fat diets followed by low-dose streptozotocin injection in type 2 DM rats (Li et al, 2017). Rizzo et al proposed that liraglutide exerted favorable cardiovascular effects through its direct antiatherosclerotic action, as well as its ability to prevent plaque formation and progression beyond glycemic control (Rizzo et al, 2018). We also explored the cardioprotective mechanism of liraglutide after stent implantation.…”

Section: Discussionmentioning

confidence: 93%

A GLP-1 Analog Liraglutide Reduces Intimal Hyperplasia After Coronary Stent Implantation via Regulation of Glycemic Variability and NLRP3 Inflammasome/IL-10 Signaling in Diabetic Swine

Xia

Liu

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: This study aimed to explore whether treatment with the glucagon-like peptide-1 (GLP-1) analog liraglutide reduces intimal hyperplasia after coronary stent implantation via regulation of glycemic variability, the NLRP3 inflammasome, and IL-10 in diabetic swine. Methods: Fifteen pigs were divided into a diabetes mellitus (DM) group (n = 6), a DM + liraglutide treatment group (L group) (n = 6) and a sham group (n = 3). A total of 24 everolimus-eluting stents were implanted in the left anterior descending and right coronary arteries at 3 weeks. A novel continuous glucose monitoring system (GMS) was used for 2 weeks. The means and standard deviations (SDs) were measured and calculated by the GMS. At 22 weeks, the lumen area (LA), neointimal thickness (NIT), neointimal area (NIA), and percent area stenosis (%AS) were analyzed by optical coherence tomography. Plasma tumor necrosis factor-a, interleukin-6, and interleukin-10 were assayed by ELISA. The intima protein expression levels of NLRP3, interleukin-1b, interleukin-18 and interleukin-10 were examined using Western blot analysis. Histology was used to evaluate the healing response. In an in vitro study, THP-1 cells were divided into control, high glucose (HG), HG + liraglutide, and HG + liraglutide + Exe(9-39) (a GLP-1 receptor inhibitor) groups. Results: The L group had a lower SD, NIT, NIA, and %AS; a larger LA; reduced inflammation and injury scores; lower expression levels of tumor necrosis factor-a, interleukin-6, NLRP3, interleukin-1b, and interleukin-18; and higher expression of interleukin-10 compared with those of the DM group (p < 0.05). In the in vitro study,

show abstract

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

Cited by 119 publications

References 69 publications

Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era

Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era

Anthocyanin Extract of Purple Corn Improves Hyperglycemia and Insulin Resistance of Rats Fed High Fat and Fructose Diet via GLP1 and GLP1R Mechanism

A GLP-1 Analog Liraglutide Reduces Intimal Hyperplasia After Coronary Stent Implantation via Regulation of Glycemic Variability and NLRP3 Inflammasome/IL-10 Signaling in Diabetic Swine

Contact Info

Product

Resources

About